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The human genome sequence is now available, virtually
complete. Why should oncologists bother about this data bank?
Until now most research in molecular carcinogenesis has been
directed at discovering and characterizing single ‘cancer’ genes.
Virtually all established diagnostic techniques in molecular
cancer pathology suffer from the limitation that they only tell
us what we are specifically looking for. It may well be that
a chosen molecular marker may be less relevant than another
one which was not ordered by the clinician, or was not
considered by the pathologist. Colon cancer is a nice example
to illustrate this issue. For example, patients with stage III colon
cancer seem to derive more benefit from adjuvant therapy if
their tumours retain a wild-type K-ras sequence [1, 2].
Interestingly, colon cancer with a wild-type K-ras status will
also derive particular benefit from epidermal growth factor
receptor (EGFR)-targeted treatment. Colon cancers with
microsatellite instability may be less aggressive than tumours
with stable microsatellites. Retention of 18q alleles in
microsatellite-stable tumours, and mutations of the gene for
type II TGF-b1 receptor in node-positive microsatellite-instable
colon cancers both point to a more favourable prognosis after
adjuvant chemotherapy. A glance at this literature shows that in
most papers the molecular marker of interest was carefully
studied, and one or the other additional gene included in the
analysis, but no such study provided an overall appraisal of all
molecular markers of potential clinical value in this cancer. The
established molecular diagnostic techniques are mostly too
laborious to permit the comprehensive screening of a tumour
biopsy sample for all possible types of genetic marker.
A new approach would be to screen cancer specimens for all
possible ‘gene’ problems, i.e. to obtain individual comprehensive
cancer gene expression profiles, at the RNA expression level (also
known as ‘signatures’). This is now possible with microarray
gene profiling [3, 4]. In contrast to the study of single genes and
their proteins, molecular tumour profiling is a large-scale
analysis of gene expression in a tumour using DNA microarrays
(Figure 1). DNA microarrays typically consist of rows and rows
of oligonucleotide sequence strands, or cDNA sequences lined
up in dots on a silicon chip or glass slide [3–6]. Oligonucleotide
sequences or cDNAs on the chip permit specific hybridization to
labelled mRNAs of interest extracted from a biopsy. Arrays can
accommodate up to 30 000 specific sequences on a single chip,
either chosen randomly or deliberately ‘biased’ to represent
theme parks of genes typically expressed in a cell type of interest,
e.g. ‘lymphoid genes’ in B cells (‘Lymphochip’) [6].
The Lymphochip is a cDNA microarray containing selected
genes preferentially expressed in lymphoid cells [7, 8]. Analysis
of gene expression in various lymphoid malignancies yields an
orderly picture of gene expression patterns in particular types
of lymphoma, reflecting lineage characteristics, stage of
maturation of lymphoid cells and proliferation signatures.
Diffuse large B-cell lymphoma (DLBCL, a clinically
heterogeneous group of lymphomas despite their morphological
similarity) can be split into subtypes with gene expression
profiles typical either of germinal centre B cells, or of activated B
cells. DLBCL expression signatures differ markedly between
patients who were cured, and those who eventually relapsed [8].
The promise is that such expression profiles or ‘signatures’ offer
more precise prognostic information than established prognostic
factors, such as the International Prognostic Index in NHL
(Figure 2), and eventually translate into concepts of refined
differentially targeted therapy.
Likewise, one invasive ductal breast cancer specimen may
look deceptively similar to another one on histology, but the
fate of the two women may be totally different. This is due to
inherent biological differences of the two tumours hidden in
their genome, which may be elusive to morphological
examination. Variation in gene transcription programmes
governed by specific somatic gene alterations accounts for
much of the biological diversity in human tumours. The study
of gene expression patterns in human breast cancer specimens
displays distinct molecular portraits, or gene expression profiles
providing molecular ‘fingerprints’ [9]. Tumours may be
clustered by sharing gene expression patterns, and it is likely
that such subgroups comprise clinically distinct subtypes or
entities of breast cancer. It also turns out that the overall gene
expression pattern of a breast cancer case is by and large
retained in its metastases. Figure 2 shows an analysis where T1–
2 N0 tumours that had or had not relapsed within 5 years after
diagnosis and primary treatment, show clearly distinct gene
expression profiles, respectively. Breast cancers of the basal-like
cell type, which often express neither hormone receptors nor
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Figure 2. Microarray analysis of DLBCL. About half of patients with diffuse DLBCL are cured with CHOP-type chemotherapies, and the other half relapse
and often die from their disease. Although a number of clinicopathological parameters are available to create prognostic subgroups (International
Prognostic Index), clinical and pathological information is inadequate for a neat distinction of these two subgroups. In this example, cases either cured or
cases with an eventually fatal outcome were studied for their gene expression profiles. It turns out that DLBCL with a good prognosis display a gene
expression signature that is clearly different from the profile that lights up in lymphoma cells from eventually fatal cases. Although the microarrays used in
this experiment offered thousands of genes for analysis, a neat prognostic distinction of the two clinical DLBCL subgroups can be made with a restricted and
selected group of genes (horizontal rows), in fact no more than 15 genes (modified after [8] with permission).
Figure 1. Gene expression profiling of tumours with cDNA microarrays or ‘chips’. The chip is a small flat box (upper left) which in a rectangular chamber
contains a siliconized surface loaded with single-strand nucleic acid sequences (lower left). These sequences represent either short specific oligonucleotides or cDNA
prepared from mRNA of various cells. Specific sequences are neatly arranged in rows and columns, and are ready for hybridization with a sample composed of
labelled single-stranded cRNA. A single chip may contain up to several 10 000 such sequences [representing genes, or so-called expressed sequence tags (ESTs)].
After hybridization the chip surface can be read, and the results expressed as quantitative estimates of gene expression, with respect to a scale of reference (bottom
centre). In this example mRNA from tumour 1 has been examined with the help of the chip. Gene A is overexpressed in this sample (red), and gene B is not
expressed at all (blue). Tumour 3 shows the reverse gene expression pattern, and the other samples all show distinct gene expression profiles. These raw data are
then sorted by a number of strategies. Unsupervised clustering (explained in a terribly simplified fashion!) refers to a programme that groups tumour samples
according to similar or completely distinct expression profiles. In supervised clustering, additional information on the samples is fed in before sorting, e.g. some
clinical information. In the end a limited number of genes can be pulled from such profiles which distinguish one subgroup of tumours from another one.
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HER2 (‘triple-negative breast cancer’) cannot be readily
identified by histology, but exhibit specific gene expression
profiles detectable on microarray analysis [10].
A few words of caution on the chip technology are
warranted. Currently, molecular diagnostics with DNA
microarrays do not displace time-honoured diagnostic tools
such as morphology and related techniques, as the demands on
bioinformatics to handle the impressive data flow are
considerable, and costs still excessive [3, 5]. The clinical
relevance of this technology and the new data it creates will
undoubtedly need to be refined, and tested in appropriate
clinical trials. Although global gene expression profiling of
cancers with the DNA chip technology is now a reality, the
detailed characterization of single genes and their proteins with
a possible role in the molecular pathology of cancers is far from
being old hat. New strategies to detect and characterize human
proteins in biological material (including clinical specimens)
are now mandatory and indeed on the horizon. As a concept,
proteomics is on the road to providing a new wave of
fascinating data with a great potential for cancer medicine,
since, similar to cDNA microchips, proteomic analysis provides
a survey of protein production in a tumour specimen, hence
specific protein production signatures.
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Figure 3. cDNA microchip analysis (so-called supervised classification on prognosis gene expression signatures) of samples from women with early node-
negative breast cancer. In this example, tumour tissue samples from women with T1–2 N0 stage early breast cancer were analysed with microarrays. For data
analysis, cases were split into those who remained disease free for at least 5 years, and those who relapsed within 5 years after diagnosis and primary treatment
(so-called supervised clustering analysis of chip data). The established clinical and biological prognostic parameters in breast cancer (T stage, N stage, receptor
status, etc.) did not permit prediction with any accuracy of which women would remain disease free or relapse. In the molecular analysis, genes have been ordered
according to their correlation with the two clinical prognostic patient groups. The microchip analysis lights up gene expression profiles that clearly differ between
tumours treated successfully, and those cases that had relapsed within 5 years after diagnosis. In women with no evidence of metastases after 5 years of follow-up,
genes with low expression cluster to the upper left of the panel (lighting up in green), and overexpressed genes (depicted in red) are grouped in the upper right
sector of the panel. The reverse pattern or expression profile is seen in the group of women who relapsed (modified after [9] with permission).
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